



PRESS RELEASE

ASLAN PHARMACEUTICALS TO PARTICIPATE IN THE 2021 CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE

Menlo Park, California, and Singapore, September 22, 2021 – ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20am ET. The conference will be held from September 27 to September 30, 2021.

A live webcast of the presentation will be available on September 30 at 9:20am ET and a replay will be archived for 365 days. To access the webcast, go to the News & Events section in ASLAN's Investor Relations website at www.ir.aslanpharma.com or the following link: <https://wsw.com/webcast/cantor12/asln/2083340>

Ends

Media and IR contacts

Emma Thompson

Spurwing Communications

Tel: +65 6206 7350

Email: ASLAN@spurwingcomms.com

Ashley R. Robinson

LifeSci Advisors, LLC

Tel: +1 (617) 430-7577

Email: arr@lifesciadvisors.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on [LinkedIn](#).